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Background: The evaluation of any new cardiac valvular prosthesis should go beyond the classical morbidity
and mortality rates and involve hemodynamic assessment. As a proof of concept, the objective of this study was
to characterise for the first time the hemodynamics and the blood flow profiles at the aortic root in patients
implanted with BioValsalva™ composite valve-conduit using comprehensive MRI and computer technologies.
Methods: Four male patients implanted with BioValsalva™ and 2 age-matched normal controls (NC) underwent cardiac
magnetic resonance imaging (MRI). Phase-contrast imaging with velocity-mapping in 3 orthogonal directions was
performed at the level of the aortic root and descending thoracic aorta. Computational fluid dynamic (CFD) simulations
were performed for all the subjects with patient-specific flow information derived from phase-contrast MR data.
Results: The maximum and mean flow rates throughout the cardiac cycle at the aortic root level were very comparable
between NC and BioValsalva™ patients (541 ± 199 vs. 567 ± 75 ml/s) and (95 ± 46 vs. 96 ± 10 ml/s), respectively.
The maximum velocity (cm/s) was higher in patients (314 ± 49 vs. 223 ± 20; P = 0.06) due to relatively smaller effective
orifice area (EOA), 2.99 ± 0.47 vs. 4.40 ± 0.24 cm2 (P = 0.06), however, the BioValsalva™ EOA was comparable to other
reported prosthesis. The cross-sectional area and maximum diameter at the root were comparable between the two
groups. BioValsalva™ conduit was stiffer than the native aortic wall, compliance (mm2 • mmHg−1 • 10−3) values were
(12.6 ± 4.2 vs 25.3 ± 0.4.; P = 0.06). The maximum time-averaged wall shear stress (Pa), at the ascending aorta was
equivalent between the two groups, 17.17 ± 2.7 (NC) vs. 17.33 ± 4.7 (BioValsalva™ ). Flow streamlines at the root and
ascending aorta were also similar between the two groups apart from a degree of helical flow that occurs at the outer
curvature at the angle developed near the suture line.
Conclusions: BioValsalva™ composite valve-conduit prosthesis is potentially comparable to native aortic root in
structural design and in many hemodynamic parameters, although it is stiffer. Surgeons should pay more attention
to the surgical technique to maximise the reestablishment of normal smooth aortic curvature geometry to prevent
unfavourable flow characteristics.
Keywords: Composite valve-conduit, Aortic valve, Aortic root, Aortic prosthesis, BioValsalva, Computational fluid dynamic* Correspondence: t.athanasiou@imperial.ac.uk
1The Department of Surgery and Cancer, Imperial College London, St Mary’s
Hospital, London W2 1NY, UK
Full list of author information is available at the end of the article
© 2014 Kidher et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Kidher et al. Journal of Cardiothoracic Surgery 2014, 9:193 Page 2 of 11
http://www.cardiothoracicsurgery.org/content/9/1/193Background
Aortic root aneurysm, dissection and endocarditis asso-
ciated with aortic valve dysfunction may be the most
common examples of pathological conditions that often
need concomitant replacement of aortic valve, aortic
root and ascending aorta [1]. Traditionally, the modified
Bentall technique with mechanical valve conduit is the
standard surgical procedure for such pathologies with
excellent short and long-term results [2,3]. The main
drawback of the classical modified Bentall procedure is
the use of mechanical valve which mandate the use of
anticoagulants. In addition, the increasing number of
elderly patients requiring modified Bentall procedure
make the use of biological composite valve-conduit more
appealing option. Hemodynamics is an essential aspect in
designing any vascular or valve product. Stentless aortic
valve prosthesis seems to have better hemodynamic
performance than stented valves [4] and may improve
coronary circulation up to the expected normal level
[5]. Stentless homografts have very good hemodynamic
performance and durability but their use is limited by
their availability [6], therefore stentless xenografts were
designed and introduced to overcome these problems
and maintain good hemodynamic profile similar to
homograft aortic valves, with excellent mid-term results
[7]. Although stentless xenografts roots offer good choice
and satisfactory outcome, their use is limited by their
length as they cannot be employed when the ascending
aorta needs to be replaced unless Dacron graft extension
is sutured [1]. This makes the procedure more complex,
increasing the ischemic time and risk of bleeding from
suture line.
Another important hemodynamic aspect in aortic valve
prosthesis design is the presence or absence of sinuses
of Valsalva [8]. Sinuses of Valsalva reduce the stress in
the leaflet significantly, facilitate vortex formation that
seems to help in smooth valve closure with less bending
deformation in the longitudinal direction, and reduce
the stress on the coronary anastomosis [8-10]. All the
above factors can affect the durability and performance
of the aortic bio-prosthetic valves, however, the effect
of sinuses of Valsalva on coronary circulation is still
debatable [11,12].
All the above-mentioned limitations accelerated the
designing and introduction of a new prefabricated com-
posite bio-prosthetic valve–conduit graft (BioValsalva™)
into the valve- conduit market since 2006. The BioVal-
salva™ (Vascutek Terumo, Renfrewshire, Scotland) is a
composite valve-conduit graft which consists of stentless
porcine aortic valve (elan valve™) pre-sewn to self-sealing
trilaminated vascular graft (Vascutek Triplex™). It is a one-
piece constructed graft making the procedure technically
less complex, reducing cross-clamp and by-pass time and
providing better haemostasis.Preliminary data from Europe have been published
[13-16] demonstrating good early post-operative results
with low mortality rate and superior haemostatic proper-
ties. However, until date, no study has been conducted
to assess the hemodynamic performance of the new gen-
eration of BioValsalva™ using advanced MRI and com-
puter technologies. Cardiovascular magnetic resonance
imaging (CMR) with phase-contrast velocity mapping and
subsequent offline computational fluid dynamics (CFD)
processing is a state-of-art effective imaging tool for
the visualization of the streamlines and particle traces
of the blood flow within the aortic root and thoracic
aorta [17,18].
The objective of the study was to assess the hemo-
dynamics and to characterise the blood flow profiles in
patients with implanted BioValsalva™ composite valve-
conduit, and compare these with matched normal
controls based on detailed analysis of cardiac MRI data
and patient-specific computational flow modelling as a
proof of concept assessment.
Methods
Ethical approval (10/H0717/45, North London Research
Ethic Committee 1) was granted and informed consent
was obtained from all participants prior to inclusion. All
patients with implanted BioValsalva™ pre-assembled com-
posite valve-conduit graft were eligible. Age and gender
matched healthy controls were recruited as normal
control group (NC).
Cardiovascular magnetic resonance imaging
MRI for patients was performed after the recommended
minimum safety period of four weeks post-operatively, mean
(49 ± 11 days). A Philips Achieva 1.5 T scanner (Philips
Achieva, Royal Philips, Amsterdam, The Netherlands)
with a 32 channel cardiac coil was used for all studies.
Two-dimensional phase contrast imaging was performed
in the aortic root, at the level of the annulus, and in the
descending thoracic aorta at the level of the pulmonary
bifurcation. Double oblique sections were obtained to
image the aorta in cross-section. The velocity-encoding
value was chosen as 10% above peak velocity in the direc-
tion measured and 100 phases per cardiac cycle were
obtained. Reconstructed voxel size was 1.4 × 1.4 × 10 mm.
Anatomic imaging of the thoracic aorta was achieved
using a navigator-gated balanced steady state free preces-
sion angiogram with a reconstructed voxel size of 0.5 ×
0.5 × 2 mm.
Image analysis
Morphological parameters
The three-dimensional geometry of aorta was reconstructed
from the anatomic MR images in an image processing
package Mimics (Materialise HQ, Louvain, Belgium). Each
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middle of descending aorta at the level of diaphragm with
the three branches on the arch included (Figure 1). The
morphological parameters were calculated based on the
reconstructed geometry of the aorta. The mean cross-
sectional area and maximum diameter of the ascending
aorta were measured along the fitted centreline of the
aorta from the aortic root to the arising point of the
brachiocephalic artery. The anatomic cross-sectional area
of the aortic sinus (A sinus) was obtained at the middle of
the aortic root, and the diameter of the sinus (D sinus) was







Two -dimensional cine phase-contrast MRI of blood flow
was performed in three orthogonal directions: feet-head,
left-right and anterior-posterior separately on the selected
imaging planes. The phase contrast images consisted of
magnitude and phase images in pairs, and the magnitude
images were utilized to identify and segment the anatomic
region of the aortic root. The segmented region was then
mapped to the corresponding phase image to calculate
the velocity values in reference to encoded flow velocity.
Velocity mapping was performed for all three compo-
nents, and was converted to the through-plane as well
as in-plane velocity maps over the cross section of
aortic root. By integrating the through-plane velocity
map over the cross-sectional area, the volumetric flow
was calculated at each of the 100 time points; then theFigure 1 Three-dimensional geometries of the aorta for all subjects. (
normal smooth curvature of the aorta is lost in BioValsalvaTM patients.temporal volumetric flow waveform was reconstructed
for a complete cardiac cycle. In this study, the temporal
maximum volumetric flow rate (Q max), the time-averaged
volumetric flow rate (Q mean) and the spatial maximum vel-
ocity at peak flow rate (V max) were examined. Additionally,
the effective orifice area, EOA (A orifice) was calculated,
which is defined as the area where the velocities are larger
than the spatial averaged velocity at peak flow rate [18].
The ratio of the EOA to sinus area (A orifice\A sinus) was also
calculated to further assess the function of aortic valves in
both control and patient groups. A MATLAB program
(The MathWorks, Inc, Natick, MA, USA) was developed
to carry out all the analysis of phase contrast MR images in
this study.Aortic wall compliance
The blood pressure at the root of aorta was measured by
a novel device Pulsecor (Pulsecor Ltd, Auckland, New
Zealand) that estimates central aortic pressures from the
brachial cuff pressure fluctuations [19]. It employs a
physics-based model involving pressure wave reflection
simulation to reconstruct the central pressure waveform
according to the small oscillations of the intra-arterial
pressure [19]. The Pulsecor device has been evaluated to
be an accurate non-invasive method to estimate central
aortic pressure [20]. The pressure of each subject was
measured by Pulsecor device just before their MR scans,
and the derived maximum systolic (Ps) and minimum
diastolic (Pd) pressure were utilized for the calculation of
compliance, distensibility and wall stiffness of the aortic
root.a) Normal control group and (b) BioValsalva™ patients group. The






Male [n (%)] 2 (100%) 4 (100%) _★
Age (years) 62 ± 4 66 ± 5 0.21
Age range (years) 55- 72 59- 78
White Caucasian [n (%)] 2 (100%) 4 (100%) _★
DM [n (%)] 0 (0%) 0 (0%) _★
Hypertension [n (%)] 0 (0%) 3 (75%) 0.4
Statin treatment [n (%)] 0 (0%) 3 (75%) 0.4
BMI (kg/m2) 30 ± 1.8 28.3 ± 2.8 0.35
Heart Rate 68 ± 13 64 ± 7 0.64
SBP (mmHg) 131 ± 1 129 ± 8 0.48
DBP (mmHg) 79 ± 1 68 ± 14 0.35
PP (mmHg) 53 ± 2 61 ± 21 0.64
MAP (mmHg) 96 ± 1 88 ± 7 0.35
Height (cm) 183 ± 5 176 ± 3 0.06
Weight (kg) 101 ± 11 90 ± 12 0.16
PVD [n (%)] 0 (0%) 0 (0%) _★
Marfan’s syndrome 0 (0%) 0 (0%) _★
Bicuspid aortic valve 0 (0%) 1 (25%) _★
NYHA (pre-op.) [n (%)] 0.46
Class I 2 (100%) 2 (50%)
Class II 0 (0%) 2 (50%)
NYHA (post-op.) [n (%)] _★
Class I 2 (100%) 4 (100%)
Class II 0 (0%) 0 (0%)
Operative characteristics
Indication for surgery,
dilated aortic root and
Aortic stenosis 1 (25%)
Aortic regurgitation 2 (50%)
Aortic stenosis and regurgitation 1 (25%)
Elective 4 (100%)
CPB time (minutes) 190 ± 51
Inotropes [n (%)] 4 (100%)
Atrial Fibrillation [n (%)] 4 (100%)
Blood products 4 (100%)
> 24 intubation 2 (50%)
Hospital stay (days) 10.5 ± 2.6
Values are shown as n (%) for categorical variables and as mean ± SD for
continuous variables. ★No statistics are computed. DM: diabetes mellitus; BMI:
body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure;
PP: pulse pressure; MAP: mean arterial blood pressure; PVD: peripheral vascular
disease; NYHA: New York Heart Association; CPB: cardiopulmonary bypass.
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root provides cross-sectional area changes throughout a
cardiac cycle. The maximum systolic (As) and minimum
diastolic (Ad) aortic root area were selected, and the sys-
tolic (Ds) and diastolic (Dd) diameter of the aortic root
were determined by the area with the same correlation
as equation (1). On the basis of the area and diameter,
the wall compliance, distensibility and stiffness index β




Distensibility ¼ As−Adð Þ=Ad
Ps−Pd
ð3Þ
Stiffness Index β ¼ ln Ps=Pdð Þ
Ds−Dd
ð4Þ
Computational fluid dynamic analysis
Based on the reconstructed three-dimensional geometry
of the aortas, computational fluid dynamic (CFD) models
were built for all the subjects in normal and patient
groups. The patient-specific flow information obtained
from phase-contrast MR data and the aortic pressure data
measured with the Pulsecor device was applied to the
computational model as boundary conditions. The three-
directional encoded velocity profiles were mapped to the
cross section of the aortic root in the model both spatially
and temporally. The aortic pressure waveform was applied
to the model outlet at the middle of descending aorta. The
flow exiting through the three branches on the aortic
arch was determined by the flow difference between the
two MR imaging planes at the ascending and thoracic
descending aorta. Blood was treated as a Newtonian
and incompressible fluid with a dynamic viscosity of
4.0 mPa and a density of 1060 kg/m3, and the aortic
walls were assumed to be rigid with no slip condition.
The 3D geometries were exported into ICEM CFX
(ANSYS) for mesh generation. The computational mesh
consisted of 3D hexahedral cells with higher resolution
in the fluid boundary layer at the wall, and mesh sensi-
tivity test was carried out to ensure mesh independence
of the simulation results.
The Navier–Stokes equations were solved numerically
with a commercial finite-volume-based CFD solver (ANSYS
CFX 14). The laminar-turbulent transitional version of
the hybrid shear stress transport turbulence model [22],
which incorporates empirical correlations to cover a
range of transition mechanisms that lead to turbulent
(chaotic) flow, was employed in the simulations to capture
possible transitional flow in the aorta.
All simulations were carried out for three cardiac cycles
to achieve a periodic solution with optimized time stepand convergence criteria, and the results presented here
were obtained in the third cycle. Results were analysed
using post-processing software ENSIGHT 10 (CEI Inc,
NC, USA). One of the most important parameters, time-
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averaging the time-varying wall shear stress (WSS) over
the cardiac cycle.Statistical analysis
Formal statistical analysis was not clinically important in
such proof of concept study with small number of sub-
jects. However for descriptive purpose, statistical analysis
was performed using IBM SPSS Statistics software ver-
sion 20.0 (IBM Corp., Armonk, NY, USA) and Microsoft
Excel 2010. Participants’ characteristics were expressed
as mean ± standard deviation (continuous variables) and
as frequencies (categorical variables). Statistical signifi-
cance was considered where P ≤ 0.05. Comparative ana-
lysis between patients and control groups was carried
out using non- parametric independent samples test
(Mann–Whitney U) for continuous variables, and Fisher’s
exact test for categorical variables.Results
Four white Caucasian male patients and two age and
gender-matched NC were recruited. All patients had
good left ventricular (LV) function prior to surgery, and
they were generally well and asymptomatic at the MRI
scan date, while the NC were disease and symptoms
free, independent and on no regular medication, Table 1
describes the clinical characteristics of both groups. All
patients underwent elective surgery, without history of
Marfan’s syndrome. Post-operatively, all patients devel-
oped atrial fibrillation which all responded to treatment
and reversed back to sinus rhythm before discharge.Table 2 Hemodynamic parameters
Control (n = 2)
Cases #1 #2 Mean
A mean (cm
2), ascending aorta 6.5 9.7 8.1 ± 2.2
D max (cm), ascending aorta 3.0 3.4 3.2 ± 0.28
A sinus (cm
2), aortic sinus 7.8 10.1 8.9 ± 1.6
D sinus (cm), aortic sinus 3.15 3.58 3.36 ± 0.3
Q max (ml/s) 682 400 541 ± 199
Q mean (ml/s) 128 62 95 ± 46
V max (cm/s) 238 209 223 ± 20
A orifice (cm
2) 4.23 4.58 4.40 ± 0.24
A orifice\A sinus 0.56 0.52 0.54 ± 0.03
TAWSSmax (Pa) 19.13 15.22 17.17 ± 2.7
Compliance (mm2 • mmHg−1 • 10−3) 25.6 25 25.3 ± 0.4
Distensibility (mmHg−1• 10−3) 4.06 2.6 3.33 ± 1.03
Stiffness index β 0.21 0.26 0.23 ± 0.03
A mean: aortic cross-sectional area; D max.: aortic maximum diameter; A sinus: sinus cro
Q mean: mean flow rate throughout the cardiac cycle; V max: spatial maximum veloci
maximum time-averaged wall shear stress.Morphologic parameters
The geometries of aorta from patients and NC groups are
presented in Figure 1. It can be observed that the normal
smooth curvature of the aorta is lost in BioValsalvaTM
patients, this is due to the development of two angles: one
at the ascending aorta level and one distal to the left
subclavian artery. The cross-sectional area (A sinus) and
maximum diameter (D sinus) at the aortic root level were
comparable between NC and BioValsalva™ patients, 8.9 ±
1.6 vs. 7.9 ± 0.9 cm2, and 3.36 ± 0.3 vs. 3.18 ± 0.15 cm re-
spectively, Table 2. This hold true at the level of proximal
ascending aorta (A mean and D max), 8.1 ± 2.2 vs. 6.5 ±
0.31 cm2, and 3.2 ± 0.28 vs. 2.9 ± 0.12 cm respectively.Hemodynamic parameters
Flow rate and velocity
There was no significant difference between patients and
NC in heart rate, blood pressure, height, weight and they
all were functionally asymptomatic at the time of MRI
scan (Table 1). Table 2 describes the main hemodynamic
parameters of the NC and BioValsalva™ patients. The
maximum flow rate (Q max) and mean flow rate (Q mean)
throughout the cardiac cycle at the aortic root level were
very comparable between NC and BioValsalva™ patients
(541 ± 199 vs. 567 ± 75 ml/s) and (95 ± 46 vs. 96 ± 10 ml/s),
respectively. The temporal profile of the flow rate for each
case is presented in Figure 2, the shape of the flow rate
waveform at the aortic root of the BioValsalva™ patients
was very similar to that of NC. The maximum velocity
(V max (cm/s)) was higher in patients in comparison to
NC (314 ± 49 vs. 223 ± 20).Patients (n = 4)
#1 #2 #3 #4 Mean P-value
6.6 6.4 6.3 7.0 6.5 ± 0.31 0.35
2.9 2.9 2.8 3.1 2.9 ± 0.12 0.16
7.7 8.8 6.8 8.5 7.9 ± 0.9 0.35
3.13 3.34 3.0 3.28 3.18 ± 0.15 0.35
551 650 597 473 567 ± 75 1.0
99.8 107 98 81.4 96 ± 10 1.0
240 336 340 342 314 ± 49 0.06
2.91 2.95 2.47 3.61 2.99 ± 0.47 0.06
0.48 0.39 0.38 0.42 0.42 ± 0.04 0.06
15.15 24 12.89 17.31 17.33 ± 4.7 0.64
9.3 12.4 18.6 10.2 12.6 ± 4.2 0.06
1.35 1.62 2.61 1.24 1.7 ± 0.62 0.16
0.52 0.35 0.32 0.52 0.43 ± 0.11 0.06
ss-sectional area; D sinus: sinus diameter; Q max: temporal maximum flow rate;
ty at peak flow rate; A orifice: effective orifice area at peak flow rate; TAWSmax:
Figure 2 Volumetric flow rate waveforms and spatiotemporal velocity profile. a) Shows the similarity in volumetric flow rate waveforms at
aortic root between the normal controls and BioValsalva™ patients. b) The spatiotemporal through-plane velocity profile at aortic root of subject
Normal #1 (top) and Patient #1 (bottom), the velocity profile of the BioValsalva™ was steeper and with higher peak than the normal.
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Over the cross section area of the aortic root, the through-
plane and in-plane components of flow velocity were
derived from three-direction encoded flow information.
The spatiotemporal velocity profile (4-time points) is
shown in Figure 2. The velocity profile of the BioValsalva™
was steeper and with higher peak than the NC. The in-
plane flow is usually much lower compared to the trough-
plane component which is the main direction of the flow,
but it could show the secondary flow patterns in the region
therefore observing the presence of retrograde, vortex or
separate flow. The in-plane velocity is visualized as vectors
on the cross-sectional plane and the through-plane velocity
colour coded for subject Normal #1 and Patient #1
(Figure 3). The in-plane flow is quite organized in the
orifice area in both subjects, however the patient subject ismore likely to have swirl near the edge of orifice area and
relatively larger retrograde flow in the surround region.Effective orifice area
The EOA at peak flow rate (A orifice (cm
2)) of the NC was
more than 30% larger than that in BioValsalva™ patients,
4.40 ± 0.24 vs. 2.99 ± 0.47. Using the ratio of EOA to sinus
cross sectional area (A orifice\A sinus) makes the difference
between the two groups less evident, 0.54 ± 0.02 (control)
vs. 0.42 ± 0.04 (BioValsalva™), Table 2. Visual illustration of
the effective orifice area at peak flow rate above the valves
was constructed (broken lines) from the colour-coded vel-
ocity map, Figure 4. As shown, the shapes in BioValsalva™
are less regular and smaller with wide margin between the
orifice and edge of the sinus.
Figure 3 The in-plane and the through-plane velocities at aortic root. The in-plane velocity projected on the cross section area of aortic root
(vectors) and the through-plane velocity (color contours) are visualized for subject Normal #1 (top) and Patient #1 (bottom). Although the in-plane flow
is organized in the orifice area in both subjects, the BioValsalva™ patient is more likely to have swirl near the edge of orifice area.
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Native aortic wall is more elastic than the BioValsalva™
conduit with twofold compliance (mm2 • mmHg−1 • 10−3)
value (25.3 ± 0.4 vs. 12.6 ± 4.2). Superior elastic properties
of the native aortic wall were also confirmed by other
aortic stiffness indices such as distensibility and stiffness
index as shown in Table 2.Figure 4 The effective orifice area (EOA). Colour-coded velocity map sh
subjects, (a) Normal control group and (b) BioValsalva™ patients group. ThWall shear stress (WSS)
The maximum time-averaged wall shear stress, TAWSS max
(Pa) was equivalent between the two groups, 17.17 ± 2.7
(controls) vs. 17.33 ± 4.7 (BioValsalva™ patients), Table 2.
Using Normal #1 and Patient #1 as representing cases, gen-
erally, in NC, TAWSS was higher on the anterior and right
segments of the aortic root and ascending aorta, while inowing the EOA at peak flow rate above the valves (broken lines) for all
e shapes of the EOA in BioValsalva™ are less regular and smaller.
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the ascending aorta and anterior-superior segment of the
proximal aortic arch, Figure 5. The maximum TAWSS
in NC was localised at the sinus area while in BioVal-
salva™ patients was at the outer curve of the ascending
aorta just distal to the suture line, Figure 5.
Blood flow pattern
Blood flow patterns are displayed by instantaneous flow
streamlines (Figure 6). The central part of the flow was
more organised and comparable between the two groups.
The flow at the outer curvature of the ascending aorta
was more uniform and streamlined in the NC with mini-
mum disturbance, while in BioValsalva™ patients more
disturbed flow with recirculation was noticed at the nearly
right-angle that developed at the suture line.
Discussion
Our literature search could not identify any study investi-
gating BioValsalva™ functional performance using similar
methodology. Therefore there were no previous results to
compare with. The number of studies investigated BioVal-
salva™ is limited and focusing mainly on mortality and
operative morbidity rates [13-16,23]. Few of them have
performed routine post-operative trans-thoracic echo-
cardiography to assess cardiac function, trans-valvular
gradient paravalvular leak, and valvular regurgitationFigure 5 The time-averaged Wall Shear Stress (TAWSS) for
subject Normal #1 and Patient #1. The maximum TAWSS values
were comparable between the two groups, but the spatial
distribution of areas with high wall shear stress was different.[15,16,23]. Two studies assessed the EOA of earlier gener-
ation, one use CT scan [16], and the other used trans-
thoracic echocardiography [13].
The design of valvular or vascular prosthesis is usually
inspired by the design of the native tissue to achieve
maximum possible similarity in structure and function.
The availability of advanced imaging and computational
technology makes the assessment of the degree of similar-
ity between such prosthesis and normal tissue achievable.
From structural design point, BioValsalva™ composite
valve-conduit graft is comparable to native tissue in
terms of biological valve, tricuspid design, stentless valve
frame, coronary sinuses and proportionally sized conduit.
From functional point, they seem very comparable to nor-
mal tissue in term of maximum flow rate (ml/s), mean
flow rate, flow rate waveform (Table 2 and Figure 2). In
addition, cross-sectional area and maximum diameter
of aortic root and ascending aorta, were also compar-
able between the two groups (to some extent higher in
the control group).
However, though the overall cross-sectional area and
maximum diameter at the sinus level was comparable
between the two groups which may indicate correct
intra-operative prosthetic size selection, the EOA (A orifice)
at peak flow rate was smaller in BioValsalva™ patients
(4.40 ± 0.24 vs. 2.99 ± 0.47 cm2). This difference might
be inevitable due the space occupied by the prosthetic
valve frame and suturing mattress as indicated by the
wide margin between the effective orifice and the edge
of the sinus (Figure 4), it may also suggest that BioVal-
salva™ valve opening is not free and wide as the normal
valve. Other factor that might contribute to the differ-
ence in EOA is the body size, the height (cm) of healthy
control was markedly taller than the patients (183 ± 5
vs. 176 ± 3), which may also explain the differences in
the aortic cross-sectional area and aortic maximum
diameter (A mean: D max.; A sinus and D sinus). Two previous
studies assessed the EOA of earlier generation, the results
of both were smaller than what we found using MRI scan
in newer generation of the prosthesis. The EOA was 2.2 ±
0.3 and 2.4 ± 0.4 cm2 for the 25- and 27-mm prostheses
when assessed with CT scan [16], and 1.9 ± 0.3 cm2 when
assessed with trans-thoracic echocardiography [13].
However, the global hemodynamic performance of the
BioValsalva™ was not affected by this difference in the EOA.
Smaller EOA has caused higher maximum velocity (cm/s)
in the patients group (314 ± 49 vs. 223 ± 20), as a small
orifice produces high-velocity jet into the aortic root, thus,
the spatiotemporal velocity profile of the BioValsalva™ was
steeper and faster than the control (Figure 2).
Another difference was in the elastic property of the
vascular (aortic) conduit. As expected, the BioValsalva™
conduit is stiffer than the native aortic wall which has
higher compliance and distensibility. This is because native
Figure 6 Flow streamlines for subject Normal #1 and Patient #1. The flow at the outer curvature of the ascending aorta was more uniform
and streamlined in normal aorta in comparison to the BioValsalva™ patient.
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proximal location, is rich in elastin tissue [24]. Whether or
not the rest of the normal aorta can counterbalance this
stiffness to deliver steady normal flow at the periphery need
to be assessed in future study.
Flow streamlines demonstrated that the flow pattern
was also comparable between the two groups apart from
the more disturbed and helical flow that occurs at the
outer curvature of the nearly right-angle turn at the
ascending aorta level. From the site and level (high above
the valve) of this helical flow, it seems to be related to
the sharp angle in the flow pathway, makes the surgical
technique more accountable to this difference than the
prosthetic design. Though the TAWSS max (Pa), were alsocomparable between the two groups, the spatial distribu-
tion of areas with high wall shear stress was different
between the two groups. By examining the close correlation
between flow streamlines and TAWSS maps (Figures 5
and 6), the difference in the TAWSS could be due to:
the difference in the maximum flow velocity (high-speed
jet in the BioValsalva™) through the valve would result in
higher shear stress on the aortic wall; the development
of nearly right-angle turn at the ascending aorta near
the anastomosis (suture) line which might cause more
disturbance to the aortic blood flow.
Our findings are in line with previously published results
using similar technology in normal controls and xenograft
aortic root replacement patients (Medtronic Freestyle,
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our results and methodology [18]. The shapes of the flow
rate waveforms were also very similar between the studies.
Interestingly, the mean EOA was also comparable between
the two studies for both patients and healthy controls,
and the spatiotemporal velocity map of our control and
BioValsalva™ were also similar to the published normal
and xenograft respectively [18].
Limitations
One could argue the small number of participants re-
cruited, however, considering the proof of concept nature
of the study and the significant time and effort needed for
imaging data reconstruction and computational model-
ling, bigger number of subjects would not be necessary.
Though unlikely to change the general direction of the
results, coincidently, all BioValsalva™ patients were male,
therefore the effect of gender on the results cannot be
confirmed. Another limitation is that coronary flow rate
was not assessed, this could shed some light on whether
the difference in aorta geometry and conduit compliance
can affect coronary circulation.
Conclusions
Combined Cardiac MRI and Computational Modelling
Technology is an effective method of assessing valvular
and vascular prosthesis from structural and functional
point of view and it should be considered as a part of
validation assessment of any new prosthesis. BioVal-
salva™ composite valve-conduit prosthesis is potentially
comparable to native aortic valve and aorta in structural
design and in many functional hemodynamic patterns,
further larger study to confirm these finding is desired.
The functional differences between BioValsalva™ and nor-
mal aortic valve are mainly in the elasticity of the vascular
conduit, therefore future design development should focus
on this aspect. Surgeons should pay more attention to
the surgical technique they use in sizing and suturing
to maximise the reestablishment of normal smooth aortic
curvature to prevent unfavourable flow characteristics.
Future larger studies using such technology should also
consider exploring the clinical impact of unfavourable
hemodynamic parameters and the effect of proximal
hemodynamic on distal circulation.
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